The study of investigators indicated that TMZ can up-regulate dopamine D2 receptor (DRD2) expression, and mediates Ferroptosis inhibition and chemoresistance of GBM. The clinical data also proved that the DRD2 expression in recurrent GBM is significantly higher than that in primary GBM. Moreover, the DRD2 antagonist haloperidol can attenuate the above function of DRD2, and increase the sensitivity of GBM to the TMZ by inducing fatal autophagy and ferroptosis. In xenograft mice, the combined usage of haloperidol and Temozolomide (TMZ) can significantly inhibit tumor growth and increase overall survival. The investigators' findings have been published in Clinical cancer research. Haloperidol known as a butylbenzene antipsychotic drug, has been widely used in several kinds of mental illnesses, such as depression, schizophrenia, and Bipolar disorder. And the safe dosage of the haloperidol is clear so far. So in this study, the investigators will recruit the patients who suffered from recurrent GBM, and evaluate the effectiveness of single TMZ chemotherapy or combined with haloperidol.

Start Date01 Dec 2024

Sponsor / Collaborator

Southern Medical University

NCT06395428 / Not yet recruitingPhase 4IIT

Haloperidol for Pain Control in Patients With Acute Musculoskeletal Back Pain in the Emergency Department

Single center, double-blind, randomized, controlled trial in patients who present to the emergency department (ED) with a chief complaint of back pain. A total of 150 patients age 18-65 presenting to the emergency department with chief complaint of backpain will be enrolled from April 2024 - April 2025. Patients will be randomized and symptom levels will be recorded at 30, 60, 90, minutes. Follow-up will be performed by telephone at 24 hours.

Start Date31 May 2024

Sponsor / Collaborator

Western Michigan University Homer Stryker M.D. School

[+1]

TCTR20240417001 / Not yet recruitingNot ApplicableIIT

A prospective observational study on QTc prolongation after receiving intravenous or intramuscular haloperidol injection for the management of acute agitation in hospitalized psychiatric patients

Start Date01 May 2024

Sponsor / Collaborator-

100 Clinical Results associated with Haloperidol

100 Translational Medicine associated with Haloperidol

100 Patents (Medical) associated with Haloperidol

20,145

Literatures (Medical) associated with Haloperidol

30 Jun 2024·Acta neurologica Taiwanica

Treatment of Intracranial Hemorrhage Induced Hemichorea- Hemiballism by Low-Frequency Repetitive Transcranial Magnetic Stimulation.

Article

Author: Nakaya, Yuka ; Asano, Rei ; Hayashi, Koji ; Kobayashi, Yasutaka ; Hayashi, Kouji ; Fujita, Kazuki ; Suzuki, Asuka ; Kawabata, Kaori ; Sato, Mamiko

An 80-year-old woman with a history of rheumatoid arthritis, hypertension, and hyperlipidemia, and no family history of hyperkinesis developed suddenly involuntary movement and visited our hospital two-day after onset. Neuro-examination revealed hemichorea-hemiballismus in the right side of the body, including the face (Suppl. video). Blood tests revealed neither hyperglycemia nor acanthocyte. Brain MRI showed acute microbleeding in the left subthalamic nucleus (Figure 1A-C). Although she was treated with haloperidol (max. 4.5 mg/day), hemichorea-hemiballismus did not subside. Repetitive transcranial magnetic stimulation (rTMS) with a low-frequency protocol (LFP) (1 Hz, 1200 pulses, with a stimulus intensity of 90% of the resting motor threshold, 3 days/week for 2-week) was applied to the left precentral knob (Figure 1D). Its effect was drastic, as the symptoms disappeared for half-hour after rTMS. Hemichorea-hemiballism then reappeared but was attenuated by repeated rTMS. The symptoms disappeared after one-month. Subthalamic nucleus lesions can develop hemichorea-hemiballism (1). According to a study on Huntington's disease and diabetic hemichorea-hemiballism, increased thalamocortical drive may increase the excitability of excitatory and inhibitory circuits of the frontal cortex as the etiologies of hyperkinesia (2-3). However, the target points of rTMS in treating hemichorea-hemiballism have not been consistent in literature. Moreover, rTMS with a LFP on the bilateral supplementary motor areas is effective in treating chorea in Huntington's disease (2). Additionally, rTMS on the ipsilateral precentral knob (primary motor cortex) with continuous θ burst stimulation (cTBS), which decreases the excitability and inhibitory cortical circuits, was effective in treating contralateral hemichorea caused by midbrain hemorrhage (3). Similar to cTBS, LFP can suppress cortical excitation (4); therefore, we applied rTMS with LFP on the primary motor cortex to treat hemichorea-hemiballism. Our results were drastic for both short- and long-term efficiency. This is the first report of the efficacy of rTMS with LFP in treating hemichorea-hemiballism caused by encephalorrhagia.

30 Jun 2024·Acta neurologica Taiwanica

Treatment of Intracranial Hemorrhage Induced Hemichorea- Hemiballism by Low-Frequency Repetitive Transcranial Magnetic Stimulation.

Article

Author: Nakaya, Yuka ; Asano, Rei ; Kobayashi, Yasutaka ; Hayashi, Koji ; Fujita, Kazuki ; Hayashi, Kouji ; Suzuki, Asuka ; Kawabata, Kaori ; Sato, Mamiko

01 Mar 2024·Pest management science

2,4‐Di‐tert‐butylphenol and 7‐hydroxy‐3‐(2‐methylpropyl)‐2,3,6,7,8,8a‐hexahydropyrrolo[1,2‐a]pyrazine‐1,4‐dione: two natural products from Serratia marcescens Ha1 and their herbicidal activities

Article

Author: Liu, Sijia ; Zhao, Han ; Tian, Ci ; Ma, Shujie ; Zhang, Lihui ; Wang, Yizhen ; Gao, Ming ; Dong, Jingao

Abstract:

BACKGROUND:

Weeds are one of the critical factors that negatively affect crop yield and quality. Microbial herbicides are a research hotspot for novel herbicides owing to their environmental safety and lack of weed resistance. In the current study, the active ingredients of Serratia marcescens Ha1, a new microbial herbicide, were investigated for their effectiveness against agricultural weeds using bioassay‐guided fractionation.

RESULTS:

The results revealed that petroleum ether and ethyl acetate extracts of S. marcescens Ha1 had high herbicidal activity. Forty‐nine compounds were identified from the petroleum ether extract, including 2,4‐di‐tert‐butylphenol (DB; C14H22O, 38.82%), ethyl 14‐methyl‐hexadecanoate, 1‐nonadecene, and [1,1′‐biphenyl]‐2,3′‐diol, 3,4′,5,6′‐tetrakis. Of these, DB showed significant inhibitory effects on root and shoot growth in Amaranthus retroflexus, with half‐maximal inhibitory concentration (IC50) values of 389.17 and 832.44 mg L−1, respectively. In addition, 7‐hydroxy‐3‐(2‐methylpropyl)‐2,3,6,7,8,8a‐hexahydropyrrolo[1,2‐a]pyrazine‐1,4‐dione (HPD) was identified as the major active ingredient in the ethyl acetate extract of S. marcescens Ha1 using bioassay‐guided fractionation, with IC50 values of 439.86 and 476.95 mg L−1 against A. retroflexus shoot and root growth, respectively. Scanning electron microscopy indicated that DB and HPD exert destructive effects on A. retroflexus root, and the damage is gradually aggravated with increasing treatment time and concentration.

CONCLUSION:

The S. marcescens Ha1 extract and its active compounds DB and HPD exhibit significant herbicidal activity, which could be utilized further for the development of microbial herbicides. © 2023 Society of Chemical Industry.

News (Medical) associated with Haloperidol

18 Jun 2024

·www.globenewswire.com

Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders

CELEBRATION, Fla. and ELK GROVE VILLAGE, Ill., June 18, 2024 (GLOBE NEWSWIRE) -- Orsini Specialty Pharmacy (Orsini), and Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra) today announced that Orsini is now the pharmacy partner for OLPRUVA® (sodium phenylbutyrate) for oral suspension. OLPRUVA® is a prescription medicine used along with certain therapies, including changes in diet, for long-term management of certain adult and pediatric patients with urea cycle disorders (UCDs) involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC) or argininosuccinic acid synthetase (AS). Visit OLPRUVA-Prescribing-Information.pdf (olpruva.com) to view the full Prescribing Information, including Important Safety Information. UCDs are rare genetic disorders that impair the body's ability to remove excess ammonia. People living with UCDs often suffer from ammonia buildup in the blood, potentially resulting in brain damage and neurocognitive impairments, coma and even death, if untreated. OLPRUVA is a nitrogen scavenger that removes excess ammonia. “Those living with UCDs can face tremendous long-term challenges including developmental delay and neurocognitive impairment, and we are committed to ensuring that they have access to OLPRUVA,” said Joshua Schafer, Zevra’s Chief Commercial Officer. “Orsini is built to serve rare disease communities, and we’re excited to partner with Zevra to connect UCD patients with this important treatment option,” said Brandon Tom, Orsini’s Chief Executive Officer. About Urea Cycle DisordersUCDs are a group of rare, genetic disorders that can cause harmful ammonia to build up in the blood, potentially resulting in brain damage and neurocognitive impairments if ammonia levels are not controlled. Any increase in ammonia over time is serious. Therefore, it is important to adhere to any dietary protein restrictions and have alternative medication options to help control ammonia levels. About OLPRUVA®OLPRUVA (sodium phenylbutyrate) was approved for the treatment of certain UCDs in December 2022 and is marketed under the brand name, OLPRUVA®. OLPRUVA (sodium phenylbutyrate) for oral suspension is a prescription medicine used along with certain therapies, including changes in diet, for the long-term management of adults and children weighing 44 pounds (20 kg) or greater and with a body surface area (BSA) of 1.2 m2 or greater, with UCDs, involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). OLPRUVA is not used to treat rapid increase of ammonia in the blood (acute hyperammonemia), which can be life-threatening and requires emergency medical treatment. For more information, please visit www.OLPRUVA.com. Important Safety Information Certain medicines may increase the level of ammonia in your blood or cause serious side effects when taken during treatment with OLPRUVA. Tell your doctor about all the medicines you or your child take, especially if you or your child take corticosteroids, valproic acid, haloperidol, and/or probenecid. OLPRUVA can cause serious side effects, including: 1) nervous system problems (neurotoxicity). Symptoms include sleepiness, tiredness, lightheadedness, vomiting, nausea, headache, confusion, 2) low potassium levels in your blood (hypokalemia) and 3) conditions related to swelling (edema). OLPRUVA contains salt (sodium), which can cause swelling from salt and water retention. Tell your doctor right away if you or your child get any of these symptoms. Your doctor may do certain blood tests to check for side effects during treatment with OLPRUVA. If you have certain medical conditions such as heart, liver or kidney problems, are pregnant/planning to get pregnant or breast-feeding, your doctor will decide if OLPRUVA is right for you. The most common side effects of OLPRUVA include absent or irregular menstrual periods, decreased appetite, body odor, bad taste or avoiding foods you ate prior to getting sick (taste aversion). These are not all of the possible side effects of OLPRUVA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. Ah Mew N, et al. Urea cycle disorders overview [updated June 22, 2017]. In: Adam MP, Ardinger HH, Pagon RA, et al, eds. GeneReviews® [Internet]. University of Washington; 1993-2022. Accessed March 20, 2022. About OrsiniProviding patients with comprehensive and compassionate care since 1987, Orsini is a leader in rare diseases and gene therapies. Orsini partners with biopharma innovators, healthcare providers and payors to support patients and their families in accessing revolutionary treatments for rare diseases. Through integrated rare disease pharmacy solutions including pharmacy distribution, patient services, clinical management and convenient home infusion services, Orsini simplifies how patients connect to advanced therapies. Orsini’s high-touch care model centers on experienced and trained therapy care teams that provide personalized patient care to ensure that No Patient is Left Behind™. Orsini Specialty Pharmacy holds accreditations with the Accreditation Commission for Health Care (ACHC), The Joint Commission, URAC and NABP. Orsini has earned URAC’s Rare Disease Pharmacy Center of Excellence Designation and ACHC's Distinction in Rare Diseases and Orphan Drugs. For more information, contact Orsini at 847-734-7373 ext. 505, email us at media@orsinihc.com, or visit www.orsinispecialtypharmacy.com. About Zevra TherapeuticsZevra Therapeutics is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. Our mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, the Company is overcoming complex drug development challenges to make new therapies available to the rare disease community. Expanded access programs are made available by Zevra Therapeutics and its affiliates and are subject to the Company's Expanded Access Program (EAP) policy as published on its website. Participation in these programs is subject to the laws and regulations of each jurisdiction under which each respective program is operated. Eligibility for participation in any such program is at the treating physician's discretion. For more information, please visit www.zevra.com or follow us on X (formerly Twitter) and LinkedIn. Cautionary Note Concerning Forward-Looking Statements This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the promise and potential impact of our preclinical or clinical trial data, the initiation, timing, design, or results of any clinical trials or readouts, the potential benefits of any of our products or product candidates for any specific disease indication or at any dosage. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of Zevra’s Annual Report on Form 10-K for the year ended December 31, 2023, Zevra’s quarterly report for the three months ended March 31, 2024, and Zevra’s other filings with the Securities and Exchange Commission. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release. Zevra Contact Nichol Ochsner +1 (732) 754-2545 nochsner@zevra.com Russo Partners Contacts Adanna G. Alexander, Ph.D. +1 (646) 942-5603 adanna.alexander@russopartnersllc.com Ignacio Guerrero-Ros, Ph.D. +1 (646) 942-5604 ignacio.guerrero-ros@russopartnersllc.com

Drug ApprovalOrphan Drug

13 Jun 2024

·www.sciencedaily.com

Dopamine linked to mentalizing abilities

A link between the neurotransmitter dopamine and the mentalizing abilities of healthy people has been identified. A link between the neurotransmitter dopamine and the mentalising abilities of healthy people has been identified for the first time in a new study. Mentalising describes the act of attributing and understanding mental states (such as thoughts, feelings or intentions) in other people and in oneself. Researchers at the University of Birmingham have been able to show that changing people's brain dopamine levels affects their mentalising abilities. Their results are published today in PLOS Biology. Dopamine is a neurotransmitter, a chemical messenger in the brain that is well known for the role it plays in pleasure, motivation and learning. In addition, researchers know that low levels of dopamine in areas of the brain that control movement underpin the primary symptoms of conditions such as Parkinson's disease. At the same time, socio-cognitive problems, such as difficulties with emotion recognition or mentalising, are also associated with Parkinson's -- yet no definitive link has been made between these problems and dopamine imbalances. More commonly, in fact, theory of mind difficulties have been associated with psychosocial changes such as isolation and social withdrawal that are a common feature of dopamine-related disorders. Lead author, Dr Bianca Schuster, of the University of Birmingham's School of Psychology, said: "While the mentalising abilities of people who are struggling with Parkinson's may not be the main focus of treatment, it nonetheless has a huge impact on people with the disease. Gaining a better understanding of how dopamine imbalances may affect mentalising processes in the brain could therefore be really significant for individuals, as well as gaining a better understanding of the secondary effects of the drugs prescribed for Parkinson's and other disorders." In the study, the researchers worked with a cohort of 33 healthy volunteers. They used a double blind, placebo-controlled experiment, in which participants were given haloperidol, a drug which blocks dopamine receptors in the brain. The volunteers took part in the same set of experiments on two separate days and on one of the days they were given the drug, and on the other day, a placebo. Participants were asked to complete an animations task, in which they were shown brief videos of triangles 'interacting' with each other. They were asked to interpret the videos by choosing the label they thought best described the ongoing scene. In a separate experiment, the researchers also investigated participants' ability to judge emotions depicted by whole-body point light displays (videos of actors where only the joint movements are visible; published here: Schuster et al., 2021, Journal of Neuroscience). The researchers found that after taking haloperidol, participants were significantly less able to accurately ascribe mental states to the interactions depicted in the animations. This was related to effects of the drug on emotion recognition. "The main implication of our work is that in disorders with dopamine dysfunctions, in addition to producing the primary symptoms associated with these disorders (such as motor symptoms in Parkinson's disease), the dopamine imbalance also affects individuals' socio-cognitive abilities" added Dr Schuster. "This work could have implications for the way in which we treat Parkinson's in the future, but also the way in which we use any drugs which affect the action of dopamine in the brain."

Drug Approval

20 May 2024

·www.biospace.com

Terran Biosciences Announces Development of TerXT, a Combination of Xanomeline and Trospium Prodrugs for the Treatment of Schizophrenia, and Intends to Pursue Accelerated 505(b)(2) Approval Pathway

MIAMI--(BUSINESS WIRE)-- Terran Biosciences Inc. ("Terran"), a biotech platform company developing therapeutics and technologies for patients with neuropsychiatric illnesses, has announced the development of TerXT, a combination of novel prodrugs of xanomeline and trospium designed to be long-acting treatments for schizophrenia. Terran has received notice of patent claims found to be allowable from the United States Patent and Trademark Office (USPTO) for the composition of matter for the world’s first prodrugs of xanomeline. To develop TerXT, Terran sought to overcome inherent pharmacokinetic and physical property limitations of the compounds xanomeline and trospium, such as poor colonic absorption and high aqueous solubility, by utilizing a novel prodrug strategy. These prodrugs were designed to enable fixed-dose combinations for once-daily oral administration (“TerXT”) and long-acting intramuscular injection with multi-month duration (“TerXT LAI”). These new forms could potentially allow Terran to pursue accelerated development and regulatory strategies such as the FDA 505(b)(2) approval pathway. Recent clinical trials of an oral, twice-daily, fixed-dose combination of xanomeline, a compound invented in the 1990s, and trospium, invented in the 1960s, have demonstrated safety and efficacy in treating schizophrenia. This combination has been submitted to the FDA for approval on the 505(b)(1) path and is currently undergoing FDA review, with a decision expected by September this year. If the FDA approves the xanomeline/trospium combination, Terran plans to pursue the rapid 505(b)(2) approval pathway for TerXT and TerXT LAI. This regulatory pathway could potentially enable Terran to use pharmacokinetic bridging studies and leverage existing safety and efficacy data from completed trials to bring Terran’s next-generation therapeutics to market approximately five years after the first xanomeline/trospium approval, helping to broaden access for patients, improve the use profile, and increase affordability. In order to successfully overcome the pharmacokinetic limitations of xanomeline and trospium, Terran assembled a team of the world’s experts in medicinal chemistry, resulting in over 10,000 new prodrugs designs. Terran’s PK modeling team developed a predictive model of both xanomeline and trospium across a vast spectrum of different formulation designs and release profiles to determine the optimal pharmacokinetic parameters and ratios. Terran utilized a team of 200 chemists to synthesize over 500 prodrugs, which then underwent preclinical testing, including 285 in vitro and 365 in vivo studies. “We’ve seen the prodrug approach significantly improve long-acting formulations of some of the most effective antipsychotics to date, including Aristada®, Haldol® Decanoate, and Invega Hafyera®, to the great benefit of patients,” said Sam Clark, MD, PhD, Terran’s founder and CEO, and inventor on the patent. “However, these improved forms were not developed until many years after the original compounds were first approved; in some cases, decades later. At Terran, we believe patients shouldn’t have to wait for the latest technology and we believe that our prodrugs of xanomeline and trospium will enable improvements in ease of use and quality of life on a much more rapid timescale than has historically been achieved.” ABOUT TERRAN BIOSCIENCES Terran Biosciences is a biotech platform company developing a portfolio of therapeutics and technologies for patients with neurological and psychiatric diseases. Terran has built a CNS-focused, tech-enabled drug development platform and is rapidly advancing a number of assets that include late-stage therapeutics for schizophrenia, an FDA-cleared neuroimaging software platform, and a drug design engine that has generated first-in-class and best-in-class psychedelic-based therapeutics and novel prodrugs optimized for patient use. Follow us on LinkedIn and X. For more information on TerXT visit

Clinical Study

100 Deals associated with Haloperidol

External Link

KEGG	Wiki	ATC	Drug Bank
D00136	Haloperidol	N05AD01	DB00502

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Psychotic Disorders	US	Ortho-McNeil Pharmaceutical LLC	12 Apr 1967
Tourette Syndrome	US	Ortho-McNeil Pharmaceutical LLC	12 Apr 1967
Bipolar Disorder	JP	Sumitomo Pharma Co., Ltd.	24 Oct 1964
Schizophrenia	JP	Sumitomo Pharma Co., Ltd.	24 Oct 1964

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03392376 (AID-ICU, Pubmed)	Phase 4	Delirium	1,000	Haloperidol	tifptepnkz(reimdvryfz) = haloperidol treatment reduced mortality at 1-year follow-up, but did not statistically significantly improve HRQoL tlsihdlwyv (esvwhveqmr ) View more	Positive	01 Jan 2024
				Placebo
NCT03392376 (AID-ICU, Pubmed \| Br Dent J)	Phase 4	Delirium	1,000	Haloperidol	skbywskmkv(ntbjkmigtq) = Serious adverse reactions occurred in 11 patients in the haloperidol group and in 9 patients in the placebo group. oxsfqsstif (bpawfosneb ) View more	Negative	26 Oct 2022
				Placebo
NCT03021486 (CTgov)	Phase 2/3	Locally Advanced Malignant Neoplasm \| Delirium \| Recurrent Carcinoma ... View more	70	haloperidol (Escalation Group)	lqdznyynjj(jrxmwdrexr) = bscykqyjhn vwzgbsflhc (pcboinzdlo, bjjjnfcmrd - ysuzxciwxr) View more	-	01 Sep 2022
				chlorpromazine (Rotation Group)	lqdznyynjj(jrxmwdrexr) = yfwsjuiaaa vwzgbsflhc (pcboinzdlo, xhnnbtysnq - fjppeqoxmd) View more
NCT03639558 (TREC, CTgov)	Phase 4	Aggression \| Agitation	100	Promethazine+Chlorpromazine+Haloperidol (Haloperidol + Promethazine + Chlorpromazine)	ewrbegfcyz(mmlmbfblyd) = nweumlltpc szcxzjkmqd (fjwpfywdow, gbysyvpabd - bbtfkykccc) View more	-	14 Jun 2022
				Promethazine+Haloperidol (Haloperidol + Promethazine)	ewrbegfcyz(mmlmbfblyd) = xoherapbdd szcxzjkmqd (fjwpfywdow, ldyodndoaa - xvqxmkzwom) View more
NCT04411940 (CTgov)	Phase 1	-	32	Haloperidol Tablets, Mylan Pharmaceuticals Inc. (Reference Product (Treatment A))	mowwlijakn(wskfakruxw) = qihgugpvvh wfgucvdhdm (gffvngvfwf, pwccbbsfmv - ohypqxkwjh) View more	-	08 Jun 2022
				Haloperidol Tablets, Cycle Pharmaceuticals Ltd (Test Product (Treatment B))	mowwlijakn(wskfakruxw) = mwkonswxel wfgucvdhdm (gffvngvfwf, ixwgiskpwt - vpwtnoewwy) View more
NCT04411953 (CTgov)	Phase 1	-	32	Haloperidol Tablets, Mylan Pharmaceuticals Inc. (Reference Product (Treatment A))	qlmanijxec(ufljajnmby) = ougbbsrcjp qbrsnugcnl (vusghqvndg, fdisvaccbh - qzbrkvghpn) View more	-	08 Jun 2022
				Haloperidol Tablets, Cycle Pharmaceuticals Ltd (Test Product (Treatment B))	qlmanijxec(ufljajnmby) = atrforgpvl qbrsnugcnl (vusghqvndg, allfqglejl - gklcomndyl) View more
NCT02199743 (CTgov)	Phase 4	Schizoaffective disorder \| Schizophrenia	35	Perphenazine+Lurasidone+Haloperidol	qpticuglya(slhlvryzai) = kuvunkmnlg nguulojmqo (eunelhjejr, hpcpunlfky - vrmwyceoce) View more	-	01 Mar 2021
NCT03056482 (Pubmed \| Ann Emerg Med)	Phase 4	Timothy Syndrome	33	Haloperidol	qnyxribbtr(tabkbonvye) = dqtlkfvhhv xpjvbiavvi (zspkneembv )	-	05 Nov 2020
				Ondansetron	qnyxribbtr(tabkbonvye) = zvakaeqngu xpjvbiavvi (zspkneembv )
NCT01639599 (CTgov)	Not Applicable	Postoperative Nausea and Vomiting \| Vomiting \| Genital Diseases, Female	150	Dexamethasone iv injection (Dexamethasone)	uahjyuftkd(otperepsbj) = lmkbgnwkia jpxhxyxyjr (njuxhtvvkk, nnkjkygfbf - fzjpzkznlg) View more	-	24 Aug 2020
				Dexamethasone, haloperidol (Dexamethasone, Haloperiol 1mg)	uahjyuftkd(otperepsbj) = azzwfvytqv jpxhxyxyjr (njuxhtvvkk, uyumnsftcv - lndssuilei) View more
NCT02747511 (Pubmed \| J Emerg Med)	Phase 4	Headache	118	Haloperidol 2.5 mg i.v.	hddnsgoayi(jfblehezbl) = qtwnpbxhks wcwuvowtew (znwehghytd )	Positive	10 May 2020
				Placebo	hddnsgoayi(jfblehezbl) = xrldioesdp wcwuvowtew (znwehghytd )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis